Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Rheumatology

Building Your Care Team & Long-Term Monitoring

At a Glance

Managing oligoarticular JIA requires a multidisciplinary care team, including a rheumatologist, ophthalmologist, and physical therapist. Long-term monitoring tracks disease activity using the JADAS10 score while ensuring proper growth, joint health, and a high quality of life as the child grows.

Managing oligoarticular JIA is a marathon, not a sprint. Because the disease can change over time—transitioning from persistent to extended or recurring after years of quiet—having a stable, expert care team and a consistent monitoring plan is the best way to ensure long-term health [1][2]. Read more about treatment options in Standard of Care: The Step-Up Approach to Treatment.

The Care Team

An optimal care team for JIA is multidisciplinary, meaning it brings together specialists from different fields to treat every aspect of the condition [2][3].

  • Rheumatologist: The “quarterback” of the team who manages the immune-modifying medications and overall treatment strategy [2].
  • Ophthalmologist: A critical partner who performs regular slit-lamp exams to catch “silent” eye inflammation (uveitis) [4][5].
  • Physical Therapist (PT): Helps maintain joint flexibility and muscle strength, ensuring patients can stay active and participate in sports [6][7].
  • Psychosocial Support: Navigating a chronic illness is emotionally taxing; some teams include a social worker or psychologist to support mental health and coping strategies [8][9].

Long-Term Monitoring Metrics

To ensure the treatment is working, your doctor will track specific markers at every visit:

  • JADAS10 Score: This composite score tracks the number of active joints and the overall level of inflammation. It is the “gold standard” for deciding if a treatment needs to be changed [10][11].
  • Growth and BMI: Chronic inflammation can sometimes interfere with how a child grows. Doctors monitor height, weight, and Body Mass Index (BMI) to ensure normal development [12].
  • Leg-Length Discrepancy: If one joint (like a knee) is inflamed for a long time, the increased blood flow can cause that bone to grow faster than the other. Regular measurements help catch this early [12].

Quality of Life and “Survivorship”

While the clinical goal is “inactive disease,” the ultimate goal is a high Health-Related Quality of Life (HRQoL). Even when joints look good, patients with JIA may still experience fatigue or lower physical activity levels than their peers [6][13].

  • Physical Activity: Staying active is one of the best ways to protect joints long-term. Your care team should encourage participation in gym and sports as symptoms allow [6][13].
  • The Risk of Recurrence: It is important to stay vigilant. Even after years of “drug-free remission,” the disease can flare up again [14][15]. Maintaining regular (though perhaps less frequent) follow-up appointments is essential even during periods of complete health.
  • Adult Transition: As pediatric patients move into their teenage years, the care team should begin a formal transition process to prepare them to manage their own care in the adult medical system [16][17].

By building a strong team and staying consistent with monitoring, you provide the best possible foundation for a healthy, active future.

Common questions in this guide

Who should be on a child's oligoarticular JIA care team?
A multidisciplinary JIA care team typically includes a pediatric rheumatologist to manage medications, an ophthalmologist to check for eye inflammation, a physical therapist for joint health, and psychosocial support for emotional well-being.
How do doctors measure if oligoarticular JIA treatment is working?
Doctors use specific metrics like the JADAS10 score to track active joints and overall inflammation. They also monitor your child's growth, BMI, and check for signs like a leg-length discrepancy to ensure normal development.
Why do JIA patients need to see an ophthalmologist?
Children with oligoarticular JIA are at risk for silent eye inflammation called uveitis. Regular slit-lamp exams by an ophthalmologist are critical to catch and treat this early, as it often has no obvious symptoms.
What happens if a JIA patient goes into remission?
Even after years of drug-free remission, oligoarticular JIA can flare up again. It is highly important to maintain regular check-ups with your care team to monitor for any returning inflammation or growth issues.
How do we handle transitioning JIA care as my child grows up?
As pediatric patients enter their teenage years, the care team should begin a formal transition process. This preparation helps teens learn to advocate for themselves and manage their own condition as they move into the adult medical system.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do you coordinate care with the ophthalmologist and physical therapist to ensure everyone is on the same page?
  2. 2.Does your clinic use a standard scoring system, like the JADAS10, at every visit to track disease activity?
  3. 3.If clinical remission is reached, what is your specific protocol for tapering off medications versus stopping them entirely?
  4. 4.What is your approach to 'shared decision-making' when we need to choose between different treatment options?
  5. 5.How does your practice handle the transition to adult rheumatology care?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Novel Immune biomarkers for the early stratification of oligoarthritis patients at risk of developing polyarticular extension.

    Raggi F, Pelassa S, Antonini F, et al.

    Frontiers in immunology 2025; (16()):1663663 doi:10.3389/fimmu.2025.1663663.

    PMID: 41132676
  2. 2

    PAFLAR guidelines for oligoarticular juvenile idiopathic arthritis.

    Hassan W, Mosa DM, Faleye A, et al.

    Clinical rheumatology 2026; (45(2)):1323-1336 doi:10.1007/s10067-025-07792-3.

    PMID: 41492017
  3. 3

    Pan American League of Associations for Rheumatology: Recommendations for the Treatment of Oligoarticular Juvenile Idiopathic Arthritis.

    Morel Z, Espada G, Eraso R, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2026; (32(2)):e55-e65 doi:10.1097/RHU.0000000000002316.

    PMID: 41728909
  4. 4

    Frequency and Identification of Risk Factors of Uveitis in Juvenile Idiopathic Arthritis: A Long-term Follow-up Study in a Cohort of Italian Children.

    Conti G, Chirico V, Porcaro F, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2020; (26(7)):285-288 doi:10.1097/RHU.0000000000001104.

    PMID: 31609817
  5. 5

    Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.

    Constantin T, Foeldvari I, Anton J, et al.

    Annals of the rheumatic diseases 2018; (77(8)):1107-1117 doi:10.1136/annrheumdis-2018-213131.

    PMID: 29592918
  6. 6

    Assessment of quality of life and physical activity in patients with oligoarticular juvenile idiopathic arthritis in remission.

    Polat MC, Çelikel E, Tekin ZE, et al.

    European journal of pediatrics 2024; (183(2)):955-964 doi:10.1007/s00431-023-05367-5.

    PMID: 38071637
  7. 7

    The effects of inspiratory muscle training on cardiorespiratory functions in juvenile idiopathic arthritis: A randomized controlled trial.

    Sarac DC, Bayraktar D, Ozer Kaya D, et al.

    Pediatric pulmonology 2024; (59(3)):562-573 doi:10.1002/ppul.26783.

    PMID: 38038160
  8. 8

    Biologic therapy through caregivers' eyes: insights from a multicenter pediatric rheumatology survey.

    Başer Taşkın B, Doğru Kılınç A, Karadoğan MT, et al.

    Expert opinion on biological therapy 2025; (25(11)):1257-1264 doi:10.1080/14712598.2025.2597849.

    PMID: 41324238
  9. 9

    Juvenile Fibromyalgia.

    Weiss JE, Kashikar-Zuck S

    Rheumatic diseases clinics of North America 2021; (47(4)):725-736 doi:10.1016/j.rdc.2021.07.002.

    PMID: 34635301
  10. 10

    When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?

    Polat MC, Çelikel E, Tekin ZE, et al.

    European journal of pediatrics 2024; (183(6)):2725-2731 doi:10.1007/s00431-024-05538-y.

    PMID: 38554171
  11. 11

    Therapeutic strategies for treating juvenile idiopathic arthritis.

    Mannion ML, Cron RQ

    Current opinion in pharmacology 2022; (64()):102226 doi:10.1016/j.coph.2022.102226.

    PMID: 35461129
  12. 12

    The impact of BMI on disease activity and growth outcomes in juvenile idiopathic arthritis.

    Yıldız Ç, Küçükali B, Kutlar M, et al.

    European journal of pediatrics 2025; (184(4)):259 doi:10.1007/s00431-025-06084-x.

    PMID: 40106024
  13. 13

    Functional status of Indian children with juvenile idiopathic arthritis.

    Datta D, Khatun M, Bankura B, et al.

    Rheumatology and immunology research 2024; (5(2)):126-129 doi:10.1515/rir-2024-0016.

    PMID: 39015846
  14. 14

    Changing Patterns in Treatment, Remission Status, and Categories in a Long-Term Nordic Cohort Study of Juvenile Idiopathic Arthritis.

    Glerup M, Arnstad ED, Rypdal V, et al.

    Arthritis care & research 2022; (74(5)):719-727 doi:10.1002/acr.24857.

    PMID: 35015381
  15. 15

    Evaluation of medication withdrawal in patients with non-systemic juvenile idiopathic arthritis in Japan using a web-based survey.

    Ebato T, Kishi T, Akamine K, et al.

    Modern rheumatology 2024; (34(6)):1231-1237 doi:10.1093/mr/roae016.

    PMID: 38441307
  16. 16

    A Canadian Advanced Physiotherapist Practitioner Shared-Care Model in Pediatric Rheumatology Offers Safe and Quality Care in the Management of Juvenile Idiopathic Arthritis-Comparing Key Performance Indicators with the PR-COIN Registry.

    Herrington J, Clarkin P, Singleton J, et al.

    Children (Basel, Switzerland) 2025; (12(12)) doi:10.3390/children12121675.

    PMID: 41462816
  17. 17

    Quantitative evaluation of a pediatric rheumatology transition program.

    Jensen PT, Karnes J, Jones K, et al.

    Pediatric rheumatology online journal 2015; (13()):17 doi:10.1186/s12969-015-0013-0.

    PMID: 26003474

This page provides educational information on building a care team and long-term monitoring for oligoarticular JIA. Always consult your pediatric rheumatologist for specific medical advice.

Get notified when new evidence is published on Oligoarticular juvenile idiopathic arthritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.